# US 2019/0314649 A1 · Micro- or nanoparticular multilamellar vesicles, compositions comprising the same and method for their use in skin care

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314649 A1
- Document ID: US20190314649A1
- Status: Published application
- Kind: A1
- Application number: 16/453,798
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2016-12-29
- Applicants: Nestlé Skin Health SA
- Inventors: Claire MALLARD; Yves RIVAL; Lise ANTHONIOZ
- Web page: https://patentgrep.com/patent/US20190314649A1

## CPC

- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 8/14: Liposomes; Vesicles
- A61K 8/4973: {with oxygen as the only hetero atom}
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

A micro- or nanoparticular multilamellar vesicle is constituted of concentric membranes comprising at least one non-ionic surfactant of the sucrose ester type comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated C12 to C22 fatty acid, which vesicle comprises at least a hyaluronic acid (HA), wherein the hyaluronic acid is a crosslinked hyaluronic acid. Also disclosed are a method of manufacture of such vesicle, compositions comprising such vesicle and their uses.

## Claims

### Claim 1

A micro- or nanoparticular multilamellar vesicle comprising concentric membranes, comprising:
(a) at least one non-ionic surfactant of the sucrose ester type, comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated, C12 to C22 fatty acid; and
(b) at least a hyaluronic acid, wherein the hyaluronic acid is a crosslinked hyaluronic acid.

### Claim 2 (depends on 1)

The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the degree of modification of the crosslinked hyaluronic acid with a chemical crosslinking agent is less than 15 mole %.

### Claim 3 (depends on 2)

The micro- or nanoparticular multilamellar vesicle according to claim 2, wherein the degree of modification of the crosslinked hyaluronic acid with the chemical crosslinking agent is less than 1.9 mole %.

### Claim 4 (depends on 1)

The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the degree of modification of the crosslinked hyaluronic acid with a chemical crosslinking agent is between 0.1 and 1.9 mole %.

### Claim 5 (depends on 1)

The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the crosslinked hyaluronic acid is sodium hyaluronate crosspolymer-2.

### Claim 6 (depends on 1)

The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the crosslinked hyaluronic acid is loaded onto the vesicle, into the vesicle, or both.

### Claim 7 (depends on 6)

The micro- or nanoparticular multilamellar vesicle according to claim 6, wherein the crosslinked hyaluronic acid is loaded onto the vesicle and/or into the vesicle at a concentration of between 0.01% and 5% (w/w).

### Claim 8 (depends on 7)

The micro- or nanoparticular multilamellar vesicle according to claim 7, wherein the crosslinked hyaluronic acid is loaded onto the vesicle and/or into the vesicle at a concentration of 0.175%, 0.35%, or 0.5% (w/w).

### Claim 9 (depends on 6)

The micro- or nanoparticular multilamellar vesicle according to claim 6, wherein the crosslinked hyaluronic acid is loaded onto the vesicle.

### Claim 10 (depends on 1)

The micro- or nanoparticular multilamellar vesicle according to claim 1, wherein the chemical crosslinking agent is a bi- or polyfunctional crosslinking agent comprising two or more glycidyl ether functional groups.

### Claim 11 (depends on 1)

The micro-or nanoparticular vesicle according to claim 1, further comprising a non-crosslinked hyaluronic acid, wherein up to 50% by weight of the total hyaluronic acid in the vesicle is non-crosslinked.

### Claim 12

A method of manufacturing a micro- or nanoparticular multilamellar vesicle, comprising:
(a) preparing a non-ionic surfactant phase comprising at least one non-ionic surfactant of the sucrose ester type, comprising at least one chain arising from a linear or branched, saturated or unsaturated, optionally mono- or polyhydroxylated, C12 to C22 fatty acid;
(b) preparing an aqueous phase comprising at least a hyaluronic acid, wherein the hyaluronic acid is a crosslinked hyaluronic acid;
(c) mixing the aqueous phase into the non-ionic surfactant phase with controlled stirring and heating, to form a preparation containing the multilamellar vesicle comprising surfactant bi-layers; and
(d) diluting the preparation containing the multilamellar vesicle with water.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the crosslinked hyaluronic acid is loaded onto the vesicles.

### Claim 14 (depends on 1)

A composition comprising a micro- or nanoparticular multilamellar vesicle according to claim 1, in a physiologically acceptable medium.

### Claim 15 (depends on 14)

The composition according to claim 14, comprising a concentration of the vesicle between 0.1% and 10% by weight, relative to the total weight of the composition.

### Claim 16 (depends on 15)

The composition according to claim 15, wherein the concentration of the vesicle is about 1%, about 2%, or about 3% by weight, relative to the total weight of the composition.

### Claim 17 (depends on 14)

The composition according to claim 14, wherein the vesicles are cationic vesicles, non-ionic vesicles, or a combination thereof.

### Claim 18 (depends on 14)

The composition according to claim 14, wherein the composition is formulated for topical or parenteral application.

### Claim 19 (depends on 14)

A method of caring for human skin or reducing the effects of skin ageing, comprising topically applying a composition according to claim 14 to the skin of a human subject in need thereof.
